ALK and non-small cell lung carcinoma: In a phase III randomized multicenter ASCEND-4 trial, previously untreated ALK-positive NSCLC patients were randomized to receive ceritinib or platinum-based chemotherapy until disease progression or unacceptable toxicity, including those with asymptomatic or stable brain metastases.